Synergistic Antifungal Study of PEGylated Graphene Oxides and Copper Nanoparticles against Candida albicans [PDF]
, 2020 © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).The coupling ...
Arce, Mariana +10 more
core +3 more sources
Dendrimer-based posaconazole nanoplatform for antifungal therapy
Drug Delivery, 2021 We examined formulating a new antifungal agent, posaconazole (POS) and its derivatives, with different molecular vehicles. Several combinations of drug and carrier molecules were synthesized, and their antifungal activities were evaluated against ...
Shengzhuang Tang +5 more
doaj +1 more source
Translation inhibition by rocaglates activates a species-specific cell death program in the emerging fungal pathogen Candida auris [PDF]
, 2020 Fungal infections are a major contributor to infectious disease-related deaths worldwide. Recently, global emergence of the fungal pathogen Candida auris has caused considerable concern because most C.
Brown, Lauren E. +6 more
core +1 more source
Discovery of a Novel Antifungal Agent in the Pathogen Box
mSphere, 2017 Human fungal pathogens cause over 2 million infections per year and are major drivers of morbidity and mortality. Cryptococcus neoformans and Candida albicans are two of the most common fungal pathogens of humans, together accounting for a staggering 1.4
François L. Mayer, James W. Kronstad
doaj +1 more source
Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. [PDF]
, 2019 Cryptococcal meningitis is a lethal disease with few therapeutic options. Induction therapy with fluconazole has been consistently demonstrated to be associated with suboptimal microbiological and clinical outcomes. Exposure to fluconazole causes dynamic
Aller +31 more
core +1 more source
Repurposing of terconazole as an anti Trypanosoma cruzi agent [PDF]
, 2019 Trypanosoma cruzi is the causative agent of Chagas disease, a parasitic infection endemic in Latin America. Currently there are no effective treatments for the chronic phase of the disease, when most patients are diagnosed, therefore the development of ...
Martínez Sayé, Melisa Soledad +4 more
core +1 more source
Drug repurposing strategies in the development of potential antifungal agents
Applied Microbiology and Biotechnology, 2021 The morbidity and mortality caused by invasive fungal infections are increasing across the globe due to developments in transplant surgery, the use of immunosuppressive agents, and the emergence of drug-resistant fungal strains, which has led to a ...
Qian Zhang +4 more
semanticscholar +1 more source
Msphere, 2020 Candida auris is an emerging multidrug-resistant (MDR) fungal pathogen that presents a serious global threat to human health. The Centers for Disease Control and Prevention (CDC) have classified C.
Raju Shivarathri +9 more
semanticscholar +1 more source
Role of therapeutic drug monitoring in pulmonary infections : use and potential for expanded use of dried blood spot samples [PDF]
, 2015 Respiratory tract infections are among the most common infections in men. We reviewed literature to document their pharmacological treatments, and the extent to which therapeutic drug monitoring (TDM) is needed during treatment.
Akkerman, Onno W +6 more
core +2 more sources
Antifungal Drug Development: Targeting the Fungal Sphingolipid Pathway
Journal of Fungi, 2020 Fungal infections are becoming more prevalent and problematic due to the continual rise of immune deficient patients as well as the progressive development of drug resistance towards currently available antifungal drugs.
Kyle McEvoy, Tyler G. Normile, M. Poeta
semanticscholar +1 more source